Home / Archive by category "Research" (Page 2)

Research

Medical marijuana programs — Why might they matter for public health and why should we better understand their impacts?

AbstractObjective Although cannabis is an illegal drug, ‘medical marijuana programs’ (MMPs) have proliferated (e.g., in Canada and several US states), allowing for legal cannabis use for therapeutic purposes. While both health risks and potential therapeutic benefits for cannabis use have been documented, potential public health impacts of MMPs — also vis-à-vis other psychoactive substance ...
Read More

Low-Dose Cannabinoid Type 2 Receptor Agonist Attenuates Tolerance to Repeated Morphine Administration via Regulating μ-Opioid Receptor Expression in Walker 256 Tumor-Bearing Rats.

Authors:  Zhang M, Wang K, Ma M, Tian S, Wei N, Wang G. Abstract BACKGROUND: Morphine is widely used in patients with moderate and severe cancer pain, whereas the development of drug tolerance remains a major problem associated with opioid use. Previous studies have shown that cannabinoid type 2 (CB2) receptor agonists induce morphine analgesia, attenuate morphine tolerance in normal and neu...
Read More

Medical cannabis: considerations for the Anesthesiologist and pain physician.

Authors Beaulieu P, Boulanger A, Desroches J, Clark AJ AbstractPURPOSE: New regulations are in place at the federal and provincial levels in Canada regarding the way medicalcannabis is to be controlled. We present them together with guidance for the safe use of medical cannabis and recent clinical trials on cannabis and pain. SOURCE: The new Canadian regulations on the use of medical canna...
Read More

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.

Authors Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev BHighlights•CBD-enriched medical cannabis is a promising treatment for intractable epilepsy. •Only minor and infrequent side effects were reported. •Epileptic encephalopathies respond better to CBD-enriched medical cannabis....
Read More

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

Author: Ethan B Russo Abstract Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromen...
Read More

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

Authors: Russo M, Naro A, Leo A, Sessa E, D'Aleo G, Bramanti P, Calabrò RS. AbstractOBJECTIVE : The aim of our study was to better investigate the role of Sativex® in improving pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological assessment. SETTING: Pain is a common symptom of MS, affecting up to 70% of patients. Pain treatment is often unsatisfactor...
Read More

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease

BACKGROUND AND PURPOSE Previous findings have indicated that a cannabinoid, such as Δ9-THCV, which has antioxidant properties and the ability to activate CB2 receptors but to block CB1, might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease (PD).EXPERIMENTAL APPROACH The ability of Δ9-THCV to reduce motor inhibition and provide neuroprotec...
Read More

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Author Russo EB AbstractTetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene,...
Read More

Peripherally Restricted Cannabinoids for the Treatment of Pain.

Authors: Romero-Sandoval EA, Asbill S, Paige CA, Byrd-Glover K. AbstractThe use of cannabinoids for the treatment of chronic diseases has increased in the United States, with 23 states having legalized the use of marijuana. Although currently available cannabinoid compounds have shown effectiveness in relieving symptoms associated with numerous diseases, the use of cannabis or cannabinoids ...
Read More

Cannabinoids in the management of chronic pain: a front line clinical perspective.

Author: Mary E. LynchAbstract Chronic pain is an escalating public health problem. Currently available treatments are inadequate to control chronic pain conditions, and there is a critical need for novel treatments. Over a half century of elegant preclinical research has identified the presence of a sophisticated endocannabinoid system that is part of our natural pain and immune defense netwo...
Read More
Top